
Merck’s KRAS G12C Inhibitor MK-1084 Shows Antitumor Activity in Early Trial
Merck Reports Encouraging Early Data for Investigational KRAS G12C Inhibitor MK-1084 in Phase 1 Trial for Advanced Colorectal and Lung Cancers Merck known as MSD outside the United States and…












